Drugs / HLX20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03588650 | Aug 2018 → Jun 2021 | cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-06-04 | Shanghai Henlius Biotech | Regulatory Henlius will Initiate Phase I Clinical Trialof HLX20 (Anti-PD-L1 Antibody) in Australia henlius.com ↗
HLX20, a recombinant fully human anti-PD-L1 monoclonal antibody developed by Shanghai Henlius Biotech, Inc., received a notice from Therapeutic Goods Administration (TGA)，Australia，about the approval of Phase I clinical trial for the treatment of advanced solid tumors in Australia. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-06-04 | Shanghai Henlius Biotech | Henlius will Initiate Phase I Clinical Trialof HLX20 (Anti-PD-L1 Antibody) in Australia henlius.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03588650 ↗ |
| Action | Inhibit | “This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed...” NCT03588650 ↗ |
| Modality | Monoclonal antibody | “HLX20 is a novel anti-PD-L1 monoclonal antibody.” NCT03588650 ↗ |
| Route | Other | “Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks.” NCT03588650 ↗ |